Pharmaceutical News

RSS

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

A new review on the Amazon website suggests that the natural antiviral supplement Gene-Eden may be effective in reducing the Hepatitis C viral load in people infected with the virus.

13 May 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company's innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.

13 May 2010

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Graymark Healthcare, Inc. today announced progress on Fiscal 2010 Initiatives and financial results for the Quarter ending March 31, 2010.

13 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Achillion Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 May 2010

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

In 1985 there was little hope for people with AIDS. Newspapers and television screens were filled with ghastly pictures of emaciated figures dying from a disease that had no cure.

13 May 2010

FDA Advisory Committee planned to review Lux Biosciences' NDA for voclosporin

Isotechnika Pharma Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration is scheduled to review partner, Lux Biosciences', New Drug Application for voclosporin on June 28, 2010.

13 May 2010

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

AlphaRx continues to develop Indaflex for the Chinese market

AlphaRx, Inc., has been advised by Cypress Biosciences, its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding to the termination of all Indaflex activity in the U.S.A., AlphaRx continues to develop Indaflex for the Chinese market.

13 May 2010

Advances in vaccine delivery and efficacy discussed at National Immunization Conference

Advances in vaccine delivery and efficacy were discussed at the 44th National Immunization Conference sponsored by the Centers for Disease Control and Prevention. A research study by each of the four directors from the Center for Vaccine Awareness and Research at Texas Children's Hospital was presented.

13 May 2010

Sex can affect frequency and severity of adverse effects of vaccination

Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.

13 May 2010

FDA warns of side effects from swallowing Benadryl Extra Strength Itch Stopping Gel

The U.S. Food and Drug Administration is warning consumers about potentially serious side effects from mistakenly swallowing Benadryl Extra Strength Itch Stopping Gel, an over-the-counter (OTC) product that should only be used on the skin.

13 May 2010

AHF targets BMS over pricing and policies for its HIV/AIDS drug

AIDS Healthcare Foundation will host a protest Wednesday morning, May 12th at 10:30am targeting New York-based Bristol Myers Squibb Co. over the pricing and policies for its key HIV/AIDS drug, Reyataz, one of the most expensive first-line AIDS treatment in the US, during the Bank of America-Merrill Lynch 2010 Health Care Conference.

13 May 2010

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

The U.S. Food and Drug Administration should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says a new report from the Institute of Medicine.

13 May 2010

Prescription drug instructions often lost in translation

Chicago Tribune: "Pharmacies that print prescription labels translated into Spanish often issue inaccurate or confusing instructions that could be potentially hazardous to a patient's health, according to a report in the May issue of Pediatrics journal."

13 May 2010

Scientists discover link between offspring lung function and maternal vitamin A supplementation

Vitamin A is critical to maternal health and child survival, yet in most developing countries Vitamin A deficiency is a leading cause of blindness and increased child mortality. The Johns Hopkins Bloomberg School of Public Health has long been a leader in vitamin A research, and scientists at the School recently discovered a link between offspring lung function and maternal vitamin A supplementation.

13 May 2010

Pharmaceutical News

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

Data on Qnexa to be presented at World Congress on CODHy in Prague

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

FDA Advisory Committee planned to review Lux Biosciences' NDA for voclosporin

Additional benefits of LAIAs over long-acting human insulin not been proven

AlphaRx continues to develop Indaflex for the Chinese market

Advances in vaccine delivery and efficacy discussed at National Immunization Conference

Sex can affect frequency and severity of adverse effects of vaccination

FDA warns of side effects from swallowing Benadryl Extra Strength Itch Stopping Gel

AHF targets BMS over pricing and policies for its HIV/AIDS drug

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

Prescription drug instructions often lost in translation

Scientists discover link between offspring lung function and maternal vitamin A supplementation

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News